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ABSTRACT  
The importance of pyrazole and isoquinoline-5,8-dione scaffolds in medical chemistry 
is underlined by the high number of drug currently on trading that contains these active 
ingredients. Due to their cytotoxic capability, the interest of medicinal chemists in these 
heterocyclic rings has grown exponentially especially, for cancer therapy. In this 
project, the first synthesis of pyrazole-fused isoquinoline-5,8-diones has been 
developed. 1,3-Dipolar cycloaddition followed by oxidative aromatization, established 
by our research group, has been employed. Screening of reaction conditions and 
characterization studies about the regioselectivity have been successfully performed. A 
remote control of regioselectivity, to achieve the two possible regioisomers has been 
accomplished. Through Molecular Docking studies, Structure-Activity relationship of 
differently substituted scaffolds containing our central core proved that a family of 
PI3K inhibitors have been discovered. Finally, in order to verify the promising 
antitumor activity, a first test of cell viability in vitro on T98G cell line of a solid brain 
tumor, the Glioblastoma Multiforme, showed cytotoxic inhibition  comparable to 
currently trade anticancer drugs. 
RIASSUNTO 
L’importanza degli scaffolds farmaceutici contenenti nuclei pirazolici e isochinolino-
chinonici è evidenziata dall’ elevato numero di farmaci, attualmente in commercio, che 
presentano questi nuclei all’ interno dei loro principi attivi. Grazie alla loro elevata 
capacità citotossica, l’interesse in questi eterocicli è cresciuto esponenzialmente, in 
particolar modo per quanto riguarda la loro attività anticancerogena. Per queste ragioni, 
in questo progetto, è stata sviluppata per la prima volta, una sintesi di pirazoli-
isochinolino-chinoni tricicli fusi; la metodologia utilizzata è stata una cicloaddizione 1,3 
dipolare con successiva aromatizzazione ossidativa, già ampiamente sviluppata in 
precedenza dal gruppo di ricerca. Si è studiata, quindi, l’ottimizzazione delle condizioni 
della reazione di cicloaddizione così come la sua regiochimica. Da questi studi è 
risultato possibile, attraverso il controllo di un gruppo remoto al sito di attacco, 
ottenerne l’inversione di regiochimica. Attraverso studi di Molecular Docking, poi, si è 
evidenziata l’interazione di scaffolds diversamente funzionalizzati, contenenti il core da 
noi sintetizzato, all’interno del sito attivo della proteina PI3K, dimostrandosi una serie 
di promettenti inibitori. Infine, per verificare la loro attività antitumorale, test in vitro 
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preliminari sulla linea cellulare T98G hanno mostrato un’attività citotossica per il 
Glioblastoma Multiforme comparabile a farmaci ad oggi in commercio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alma Mater Studiorum- Università di Bologna  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alma Mater Studiorum- Università di Bologna  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alma Mater Studiorum- Università di Bologna  
 
  
Table of Contents 
 
1. Introduction .................................................................................................................. 2 
1.1. Pyrazole in Medicinal Chemistry ................................................................... 2 
1.1.1. Approved drug containing pyrazole mojeties ............................................. 3 
1.1.2. Ring-fused pyrazole .................................................................................... 5 
1.1.3. Pyrazole for Cancer Therapy ...................................................................... 7 
1.2. Biological activity of isoquinoline-5,8-dione .................................................. 9 
1.3. Halogen compounds in Medicinal Chemistry.............................................. 11 
1.3.1. Fluorine in medicinal chemistry ............................................................... 14 
1.4 Pyrazole synthesis........................................................................................... 16 
1.4.1. 1,3-Dipolar cycloadditions ........................................................................ 16 
1.4.2. Synthesis of ring-fused pyrazoles ............................................................. 19 
1.4. Ring-fused quinones ....................................................................................... 21 
2. Aim of the Thesis ........................................................................................................ 25 
3. Results and Discussions .............................................................................................. 28 
3.1. Synthetic methology for the dipolarophile ................................................... 28 
3.1.1. Synthesis of Isoquinoline-5,8-diones ........................................................ 30 
3.2. Synthesis of the hydrazonoyl chloride, precursor of the 1,3-dipole .......... 35 
3.3. 1,3-Dipolar cycloaddition of the nitril-imine with the isoquinoline-5,8-
diones followed by oxidation: synthesis of tricyclic  ring-fused pyrazoles ........... 38 
3.3.1. Optimization of reaction condition ........................................................... 40 
3.3.2. Screening of the substitution on both the cycloadditition reaction partners: 
synthesis of a class of triclycic ring-fused pyrazoles .............................................. 42 
3.4. Molecular Docking and in vitro cytotoxic evaluation : pyrazole-fused 
isoquinoline-5,8-diones as a class of  promising antitumoral agent...................... 44 
4. Conclusions ................................................................................................................. 52 
5. Experimental section .................................................................................................. 56 
5.1. Synthesis of the dipolarophile ....................................................................... 57 
5.1.1. General method for the  synthesis of β-ketoesters .................................... 57 
5.1.2. General method for the  synthesis of enaminones .................................... 57 
5.1.3. General method for the  synthesis of β-nitroolefins ................................. 58 
5.1.4. General method for the  synthesis of β-amino nitroolefins ...................... 59 
5.1.5. General procedure for the synthesis of isoquinoline-5,8-diones .............. 60 
5.2. Synthesis of the 1,3-dipole ............................................................................. 62 
5.2.1. General synthesis of hydrazide ................................................................. 62 
5.2.2. General synthesis of hydrazonoyl chloride ............................................... 63 
5.3. General method for 1,3-dipolar Cycloaddition reaction ............................ 64 
5.4. General method for reduction....................................................................... 67 
6. Bibliography ................................................................................................................ 69 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
2 
 
1. Introduction 
1.1. Pyrazole in Medicinal Chemistry 
Pyrazole, term given by Ludwig Knorr in 1883, refers to a class of simple aromatic  
organic compounds of the heterocyclic series, characterized by a 5-membered ring 
structure containing two nitrogen atoms in adjacent positions. In 1959, the first 
natural pyrazole, 1- pyrazolyl-alanine, was isolated from the seeds of watermelon.
1
  
 
 
 
Fig.1 Structure of first isolated natural pyrazole 
Pyrazole derivatives have been used for long time in agrochemicals and 
pharmaceutical industry as herbicides and active pharmacuticals ingredients (APIs)s. 
After the success of pyrazole-containing drugs, due to their inhibitory capacities, the 
importance of these heterocyclic rings has exponentially grown in medicinal 
chemistry.  
 
 
 
 
 
 
Fig.2 Biological activity of pirazole-containing drugs 
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Even if they are rarely found in nature, probably due to difficulty encountered in the 
formation of N-N bonds by the living organisms, still plenty of research publications 
during last decade showed an increasing interest of synthetic as well as medicinal 
chemists in pyrazole containing compounds, in view of their wide applications in 
different fields.
2
 
 
1.1.1  Approved drug containing pyrazole mojeties  
 A large number of commercially available top selling drugs containing pyrazoles 
can be found, exhibiting antispasmodic, anti-inflammatory, antibacterial, 
antihyperglicemic, antidepressive and, more recently, antitumor activities.
3
 In order 
to underline the variety of simple substituted pyrazoles that can be found on the 
market of pharmaceuticals, few examples of commercially available drugs are shown 
below. Mepiprazole, main active ingredient of Psigodal, is an anxiolytic and 
antidepressant drug of the phenylpiperazine group, commercially available in Spain. 
It’s an α1-adrenergic receptor antagonist, producing mCPP (meta-
Chlorophenylpiperazine) as active metabolite, and has been found that, unlike other 
psycho-pharmaceuticals, has specific dopamine- and serotonin-potentiating activity 
and simultaneously has noradrenaline-blocking activity in the central nervous 
system. Thus, for example, dopamine reuptake was inhibited by 50-70% in rats by 
administration of 20 mg/kg; it showed a reduction in serotonin turnover of about 
50% and an increase in noradrenaline turnover by 60%. This combination of effects 
has not been observed heretofore in psycho-pharmaceuticals, allowing normalization 
of noradrenaline and serotonin transmitter metabolism.
4,5
  
 
 
 
 
Fig.3 Simple pyrazole use as anxiolytic and antidepressant drug 
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Secondly, Crizotinib, sold by Pfizer under the trade name of Xalkori, is a disubstituted 
simple pyrazole with antitumor properties. It acts as a ROS-1 gene (proto-oncogene-1) 
inhibitor and has obtained excellent results in clinical trials against anaplastic large cell 
lymphoma, neuroblastoma and other advanced state solid tumors.
6
 
 
Fig.4 Anticancer commercially approved by FDA drug based on pyrazole moiety 
Rimonabant is a cannabinoid receptor antagonist that reached the market in several 
countries as anorectic and anti-obesity drug, with a potential for aiding smoking 
cessation. CB1 receptors antagonists have been investigated mainly as a potential 
strategy for treating obesity and associated metabolic disorders. Despite their putative 
clinical applications, the experimental evidence heralded the notion that Rimonabant 
could induce psychiatric side effects.
7
 
 
 
 
 
 
 
Fig.5 Trisubstitued carboxamide pyrazole with multiple biological activity 
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1.1.2 Ring-fused pyrazole  
Ring-fused pyrazoles are, if possible, even more important than simple rings in the 
above mentioned applicative categories. Allopurinol, for example, is a generic drug 
used for treatment of hyperuricemia, i.e. an excess of uric acid in blood, playing a 
crucial role in the inhibition of xanthine-oxidase, an enzyme involved in the purinic 
metabolism. This molecule showed a better binding affinity to the target-protein  
compared to the corresponding Xanthine, but, due to the presence of the pyrazole ring, 
instead of the imidazole one, was not affected by the oxidative circle. It was also 
included in the World Health Organization’s List of Essential Medicine.
8
  
   
 
 
Fig 6. Allopurinol and Xanthine 
Another biologically active ring-fused pyrazole is Apixaban: developed by Bristol-
Myers Squibb in collaboration with Pfizer, actually in phase III of clinical trials for the 
excellent anticoagulant properties, it contains a N-substituted pyrazole-fused δ-lactam. 
This drug acts as an inhibitor of the Xa factor, a serine protease that plays an important 
role in the coagulation cascade.
9
 Compared to Warfarin (known under the trade name of 
Coumadin), currently the most common drug for the treatment of this disease, Apixaban 
has been found to be “not inferior” in ictus prevention and superior in secondary 
hemorrhaging’s prevention, despite some side effects.
10
 
 
Fig.7. Apixaban and Warfarin, two anticoagulant drugs 
 
 
  
 
 
 
6 
 
Moreover, condensed pyrazole derivatives have often shown antiproliferative activities 
towards a wide number of cellular lines and are often employed in anticancer drug 
discovery screening. For example, a number of reports have suggested that CK2 is a 
potential target for cancer treatment due to its overexpression in a wide variety of 
tumours, and various small-molecule CK2 inhibitors have been developed. Recently, 
based on our previous SAR (Structure-Activity Realationship) studies, benzo[g]indazole 
derivatives were synthesized, through a tricomponent cascade reaction, as novel CK2 
inhibitor candidates. In Fig. 8, the most active compounds of this class I and II has been 
reported.
11
 
 
 
 
 
 
Fig.8  Ring-fused pyrazoles exhibiting promising anticancer activity 
Finally, as another example, pyrrolo-[3,4-c]-pyrazole III (Danusertib), an Aurora kinase 
inhibitor, has advanced in phase II clinical trials for the treatment of Bcr-Abl positive 
leukemia, due to the good pharmacokinetic properties as inhibitor of Aurora kinases and 
Bcr-Abl tyrosine kinase (mitosis regulators aberrantly overexpressed in cancer cells), 
along with general safety profiles shown in phase I clinical studies. Compared with 
other hinge binder templates, its double heterocyclic core offers efficient hydrogen 
bonds interactions, improving greatly its physiochemical properties.
12
 
 
Fig.9 . Danusertib, a ring-fused pyrazole in clinical trials for the treatment of Bcr-Abl positive leukemias. 
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1.1.3 Pyrazole for Cancer Therapy 
 
Pyrazole and its derivatives have been widely studied for the development of new 
therapeutics for various diseases, including cancer. In the last decade, many researchers 
have reported a large series of pyrazole derivatives having promising anticancer 
activities, indicating the use of pyrazole motif as a powerful tool for novel anticancer 
drugs development.
13
 Recent studies have shown several diarylpyrazole derivatives 
possessing ALK5, FLT3, ERK and B-raf kinase inhibitory activities. This clearly 
suggests that the kinase inhibition may play a role for the observed cytotoxicity. In a 
2014 work of Banoglu et al.
14
, in order to get a wide library of biologically active, 
pyrazole containing compounds, a quinolinyl pyrazole carboxylic acid general scaffold, 
with a well-known cytotoxic activity against several human cancer cell lines, was 
substituted with different moieties through amidation reactions with aryl- and 
heteroaryl- substituted primary amines. Among the large number of synthesized 
molecules, compound IV was found to be the most active in sulfohodamine B assay 
with IC50 (half maximal Inhibitory Concentration) values of 1.1 μM and produced 
dramatic cell cycle arrest at G1 phase as an indicator of apoptotic cell death induction. 
 
 
 
 
 
Fig.10 N-(2-Chloropyridin-4-yl)-5-(4-methylphenyl)-1-(quinolin- 2-yl)-1H-pyrazol-3-carboxamide 
 
Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular 
signaling in response to extracellular stimuli. Due to the central role of this class of 
protein in various signal transduction-mediated events, they have been an area of 
intense investigation in the last decade. The discovery of PI 3-kinases by Lewis Cantley 
and colleagues began with their identification of a previously unknown 
phosphoinositide kinase associated with the polyoma middle T protein.
15
 They observed 
unique substrate specificity and through ion-exchange chromatographic separation of 
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the products of the lipid kinase, they discovered that this phosphoinositide kinase has 
the unprecedented ability to phosphorylate phosphoinositides on the 3' position of the 
inositol ring (Fig.11).  
 
 
 
 
 
  
Fig. 11 Example of phosphorylation by PI3K 
Hyperactivation of PI3K signaling cascades seems to be one of the most common 
events in human cancers. As the basic biology of the PIKs has become clearer, their 
roles in other various pathologies as inflammation or cardiovascular diseases was better 
understood. This led to the synthesis of new agents that weaved in this complex tree of 
signals. The central role of phosphoinositide 3-kinase activation in tumor cell biology 
has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT 
and mammalian Target Of Rapamycin (mTOR) in cancer treatment.
16
 Quinoxaline 
derivatives V were found to be a family of inhibitors of PI3K that worked very well for 
a variety of substituents (R1 and R2), with an IC50 values < 0.1 μM. Moreover, as part 
of series of pyrazoles, disclosed in a patent application as AKT inhibitors,
 
C-aryl-
pyrazole VII showed an AKT inhibition activity with an IC50 value < 0.1 M.
17 As 
another example, pyrazole VI was disclosed in a patent as a mixed inhibitor of mTOR 
(mammalian Target Of Rapamycin) and PI3K, with potentially uses in oncology.
18
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Fig. 12 Structure of pyrazole-based drugs that showed antitumoral activity 
1.2. Biological activity of isoquinoline-5,8-dione  
Isoquinoline-5,8-diones have a wide range of biological activities as antibacterial, 
antifungal, antimalarial and antitumoral agents.  
 
 
 
 
Fig.13 Structure of polysubstitued isoquinoline-5,8-dione 
This moiety is present as an important core in a number of cytotoxic agents, such as 
naturally occurring mimosamycines and cribrostatines. To underline the efficacy of the 
substrates belonging to these families as antitumoral agents, naturally occurring 
cribrostatin 7 IX, renierone X and O-demethylrenierone XI showed remarkable 
cytotoxic activities against human colon carcinoma cell line, with IC50 values 
respectively of 45, 24 and 34 nM. 
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Fig. 14 Structure of active isoquinoline-5,8-diones against colon carcinoma 
Gustafson group at the National Cancer Institute (NCI) reported the isolation of 
caulibugulones A–F, a series of novel cytotoxic isoquinoline quinones (showed in Fig. 
15) and iminoquinones, from an extract of the marine bryozoan Caulibugula intermis.
19 
They also disclosed that caulibugulones A–F exhibited IC50values of 0.03–1.67 M 
against murine tumor cells based on an in vitro cytotoxicity assay. 
 
 
 
 
 
 
 
Fig. 15 Natural isoquinolinequinone-core Caulibugulones  
 
Anticancer quinones are currently the focus of intensive research because of their 
biological activity and complex modes of action, which differ depending on their 
particular structure. They represent a class of toxicological compounds that can generate 
a variety of critical effects including acute cytotoxicity, immunotoxicity and 
carcinogenesis with a complex pathway of action not always completely explained at 
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present time. Quinones moiety are Michael acceptors, and cellular damage can occur 
through alkylation of particular cellular proteins or DNA. On the other hand, quinones 
are highly redox-active agents that can undergo either an intracellular two-electron 
reduction to hydroquinones or one-electron to semiquinone, leading to the formation of 
reactive oxygen species (ROS) like peroxide, superoxide and hydroxyl radicals that 
have been associated with aging and carcinogenesis. Pixandrone, an aza-anthraquinone 
with a isoquinolinequinone moiety, commercialized under the trade name Pixuvri, is an 
antineoplastic drug, that showed fewer toxic effects on cardiac tissues compared to its 
non-aza analogues anthracyclines, such as mitoxantrone
20
. Anthracyclines are indeed 
important chemothepy agents, however their use is often associated with irreversible 
heart damage; thus some aza-derivates were developed in order to reduce heart 
damages, maintaining the same antitumor efficacy. 
 
 
 
 
 
 
Fig. 16 Antitumoral Pixantrone and non-aza derivate Mitoxantrone 
Pixantrone stands indeed in the family of antitumor antibiotics for the treatment of 
different type of cancers, including solid tumors and hematological cancers, such as 
non-Hodgkin lymphomas, that has completed phase III clinical trials.  
1.3. Halogen compounds in Medicinal Chemistry 
A significant number of drugs and drug candidates in clinical development present 
halogenated structures. For a long time, insertion of halogen atoms on hit or lead 
compounds was predominantly performed to exploit their steric effects, through the 
ability of these bulky atoms to occupy the binding site of molecular targets. However, 
halogens in ligand-active site complexes influence several processes rather than steric 
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aspects alone. For example, the formation of halogen bonds in ligand-target complexes 
is now recognized as a kind of intermolecular interaction that favorably contributes to 
the stability of protein-ligand complexes.  
Due to their molecular complexity and diversity, secondary metabolites from natural 
sources, mainly plants, still inspire the design of drugs. Although in recent years marine 
animals have demonstrated to be rich sources of halogenated metabolites,
21
 the 
occurrence of halogenated natural products in plants is rare.
22
 Thus, it would be 
expected that halogenated drugs would have little importance in the drugs scenario, but 
this is not the case, since this class of compounds has a prominent position. Of course 
they are, in their majority, of synthetic origin. In the diagram is showed the relative 
abundance of halogenated drug classified, according to the kind of halogen by the FDA 
from 1988 to 2010.
23
 
 
 
 
 
 
 
 
Table 1. Abundance of halogenated drug approved by FDA; salts and metal complexes are excluded from 
this diagram. 
Halogen bonding refers to non-covalent weak interaction between halogen-bearing 
compounds and nucleophiles or electron rich species. With the aid of computational 
tools combined with experimental observation it was clarified that the halogen bond has 
to respect some rigorous requirements to be of some importance: distance between the 
two active species has to be minor than the sum of van der Waals radii, and the optimal 
angle has to range from 160° to 180°. Another feature is the strength of the bond, 
increasing proportionally with the weight of the halide substituent.
24
 The  first 
observation was made in cocrystal structures of 1,4-dioxane and Br2 by Hassel and 
Fluorine (57%)
Chlorine (38%)
Bromine (4%)
Iodine (1%)
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Hvoslef in 1954. One of the first systematic investigation of halogen bonding in protein-
ligand interactions, carried out by Diederich group of ETH Zurig in support with 
Novartis and Basell, focused on rationalizing the role of a halogen atom, present in an 
inhibitor of Cathepsin L, an important lysosomal endopeptidase enzyme involved in the 
initiation of protein degradation.  
 
 
 
 
 
 
 
 
 
 Fig. 17 Interaction of aryl-halogenated portion in active site 
IC50 values in 4-substituted phenyl derivatives were determined in a fluorescence assay, 
leading to the discovery that IC50 values were directly proportional to the strength of the 
halogen-bond.   
 
 
 
 
 
 
 
 
Fig.18 Effect of para-substitued aryl group shows that halogen substitutions give better inhibition of the 
protein 
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For these reasons the halogen-bond seems to be a powerful tool, comparable to the more 
investigated hydrogen bond, capable to increase the binding affinity in protein-drug 
interactions, making halogenated moieties promising candidates for drug-design and 
structure-activity relationship studies. 
1.3.1 Fluorine in medicinal chemistry 
 
 In medicinal chemistry, fluorine is generally viewed as a classical bioisoster of 
hydrogen. One example of this statement is the classical exachanging of hydrogen with 
fluorine on the purine base uracile, resulting in the anticancer drug 5-fluorouracil (5-
FU) (Fig. 19). Thereby, the fluorine chemistry provides good opportunities for 
enhancing the binding affinity of potential drug candidates. 
 
 
 
 
Fig.19 Bioisosteric exchange to give a fluorinated antitumor drug from the purine base uracile 
 
As expected from the fluorine position on the periodic table of elements, it possesses 
some extreme properties, in particular, ultimate electronegativity and oxidation 
potential. However, in the late 1940−1950s the idea of introducing fluorine into 
molecules of natural products was rather unconceivable. The prevailing wisdom of that 
time clearly suggested that fluorine is an abiotic element, and its applications were 
limited to military and special materials needs. Furthermore, quite poisonous properties 
of a few naturally occurring fluoroorganic compounds were very well known. It is 
interesting to note that discovery of fludrocortisone (XII), the first fluorine-containing 
pharmaceutical product, was a result of a systematic study on a series of 9α-halogenated 
cortisone derivatives, and the fluorinated compound was not included in the original 
study. After trying all the other halogen derivatives, they tried, just to complete the 
series, to synthetize the fluorinated compound, discovering its remarkable 
glucocorticoid activity, compared to the others.
25
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Fig. 20 Structure of Fludrocortisone 
 
There are many effects that fluorine and fluorine-containing substituents can impart to 
organic compounds. It is well known that fluorine electronegativity, size, 
omniphobicity-lipophilicity, and electrostatic interactions can dramatically influence 
chemical reactivity. The strategic use of fluorine substitution in drug design has 
culminated with the production of some of the key drugs available on the market. These 
include Fluoxetine
26
 (antidepressant, commercialized as Prozac), Faslodex
27
 
(anticancer), and Efavirenz
28
 (antiviral). Generally, the effect of fluorine on the 
biological activity of organic compounds is rather subtle and difficult to predict. 
Accordingly, quite intense structure-activity relationship studies are usually necessary 
to pinpoint the correct position of fluorine in the target molecule. Gefitinib (ZD-1839), 
developed and launched by Astra-Zeneca, is an oral epidermal growth factor receptor 
(EGFR) inhibitor used for the treatment of certain breast and lung cancers. It was first 
launched in Japan in July 2002 for the treatment of inoperable or recurrent non-small 
cell lung cancer (NSCLC), and then, it was launched in the United States as a third-line 
monotherapy.
29
  
 
 
 
 
Fig.21 Structure of EGFR-inhibitor for the treatment of breast and lung cancer  
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1.4. Pyrazole synthesis 
Conventional approaches for the preparation of substituted pyrazoles involve either the 
construction of two C-N bonds by cyclocondensation of hydrazines with 1,3-
dielectrophilic compounds (Scheme 1, via b) or the generation of one C-N and one C-C 
bond by 1,3-dipolar [3+2] cycloaddition (Scheme 1, via a). Each method has its own 
scope and efficiency limitations, however, general and efficient methodologies have 
been developed, following these general strategies, with the aim of increasing the yield 
and the regioselectivity in the preparation of substituted pyrazoles.  
 
Scheme 1. General approaches for the synthesis of pyrazole 
1.4.1 1,3-Dipolar cycloadditions 
The 1,3-dipolar cycloaddition reaction has been employed as one of the most powerful 
synthetic tools to provide substituted pyrazoles. Three main classes of 1,3-dipoles have 
been used as [C,N,N] synthons, namely, diazoalkanes, azomethine imines and 
nitrilimines; the [C,C] fragment usually comes from activated π-bonds of alkanes and 
alkynes.  
 
 
 
 
 
 
Scheme 2. Most common dipoles for 1,3-dipolar cycloadditions leading to pyrazoles 
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Compared to cyclocondensations between hydrazines and 1,3-dielectrophiles, 1,3-
dipolar cycloadditions are intrinsically more highly regioselective owing to the 
significant electronegative difference between the N and the C atom of the substrate. 
Nitrilimines are generated in situ by treatment of hydrazonoyl halides with a base. Their 
1,3-dipolar cycloaddition to alkynes (Scheme 3, via a
30
) or alkenes bearing a leaving 
group (Scheme 3, via c
31
) leads directly to pyrazoles, while addition to simple activated 
double bonds produces pyrazolines (Scheme 3, via b
30
) that must be subsequently 
oxidized to the desired aromatic pyrazole.  
Scheme 3. Nitrilimine formation and cycloaddition with alkynes (a), alkenes followed by oxidation (b) 
and alkene bearing a leaving group (c) 
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A very convenient prerogative of this synthetic strategy relies on the facile control and 
modification of the regiochemistry, as proved in our laboratories. For example, a 
catalytic amount of scandium triflate, Sc(OTf)3, as Lewis acid, is responsible for the 
inversion of the regioisomeric ratio in the cycloaddition of N-aryl-C-carboxyalkyl 
nitrilimine and an activated acetylene, such as N-phenyl-propiolamide.
32
  
 
Scheme 4. Regioselectivity reversion with Sc(OTf)3 
Moreover, the electronic nature of the activating substituent of the multiple bond acts as 
a director of regiochemistry. In particular, electron donating groups (EDG), such as 
sulfide in Scheme 5, lead to 5-substitued pyrazoles, while electron-withdrawing groups 
(EWG) such as sulfone in Scheme 5, lead to 4-substitued pyrazoles as major products. 
These experimental results were broadly investigated by our research group and were 
confirmed by computational calculations as an interaction between distorted frontier  
molecular orbitals (HOMO-LUMO) both on the dipolarophile and on the nitrilimine 
dipole.
33
 
 
  
 
 
 
19 
 
 
Scheme 5. Regioselectivity directed by acetylene substituents 
 
 
1.4.2 Synthesis of ring-fused pyrazoles 
Because of the excellent bioactivity and the wide range of application, thousands of 
papers concerning the synthesis of condensed pyrazole derivatives have been published.
 
However, it is possible to summarize all these strategies into three main classes: 
methods starting from a pre-formed ring to which the pyrazole is subsequently fused, 
methods starting from a pre-formed pyrazole to which a new ring is subsequently fused 
and, finally, methods generating both pyrazole and its fused ring at once, following one-
pot reaction procedures. Multicomponent one-pot syntheses are well known to produce 
highly functionalized, complex molecular scaffolds in very convenient, step- and atom-
economical procedures. Nevertheless, the outcome of these reactions is very often 
difficult to predict and control, rendering this strategy quite unappealing for the 
synthesis of a precise target compound. On the other hand, methods condensing a new 
cycle on the pyrazole ring suffer from the complexity of the direct functionalization of 
an heterocycle of hybrid electronic characteristics, not yet completely investigated and 
understood.  
Hence, strategies constructing the pyrazole on pre-existing rings seem to be the more 
convenient pathway to condensed pyrazole derivatives, due to the wide spectrum of 
synthetic methods for the obtainment of the heterocycle, also from very different 
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starting materials. For these reasons, our research group has quite recently reported a 
new synthetic procedure leading to cycloalkenone, lactone, thiolactone and lactam-
fused pyrazoles, employing the 1,3-dipolar cycloaddition of various nitrilimines with 
α,β-unsaturated cyclic systems (Scheme 6)
34
  
 
Scheme 6. Cycloaddition of nitrilimines with various α,β-unsaturated cyclic systems 
Finally, the regiochemistry of the reaction was broadly investigated and the 
experimental results were justified through theoretical and computational studies. In 
most cases, 5-acyl-pyrazole derivatives were found to be the major products; although, 
only small and hard dipolarophiles (cyclopentanone and α,β-unsaturated γ-
butyrolactone) reacted with electron-rich nitrilimines (such as N-p-methoxyphenyl, C-
carboxymethyl nitrilimine) under the mandatory presence of Et3N as a base, giving an 
inversion in the selectivity, in favor of 4-acyl-pyrazoles.
34
  
 
Scheme 7. Major product arising from cycloaddition-oxidation of N-p-methoxyphenyl, C-
carboxymethyl- nitrilimine and each of the shown dipolarophiles 
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To prove the applicability of this approach in the obtainment of complex structures for 
medicinal chemistry applications, an highly convergent synthesis of a novel lactam-
fused pyrazole was reported by our research group. The structure (XIII in Fig.22) 
showed interesting IC50 values in the range of 15-60 M, results comparable with 
nowadays commercially available anticancer compounds.
35
  
 
 
 
 
 
 
 
Fig. 22 Target molecule recently synthesized by research group 
1.5. Ring-fused quinones 
As already envisioned in previous chapters quinones are a class of organic compounds 
endowed with a variety of biological activities, mostly connected with their redox 
properties. A number of natural and synthetic ring-fused quinones show remarkable 
anticancer activity, and a series of synthetic 1,4-naphtoquinones have recently been 
identified as Hsp90 inhibitors. Multiple signal transduction pathways implicated in the 
regulation of cell prolification and survival are Hsp90 dependent. In a recent publication 
also ring-fused isoquinoline-5,8-diones have been identified as higly specific Hsp90 
inhibitors. In this work 1,3-dipolar cycloaddition between in situ generated nitriloxides 
from XV and 6-bromo-isoquinoline quinones XIV afforded isoxazole ring-fused 
products XVI with good regioselectivities, mediated by the presence of the bromide in 
the electrophilic site (Scheme 3, via c). The isoquinoline quinone nucleus, compared to 
the naphtoquinonic core, led to an improvement of both the binding affinity and the 
antiproliferative activity compared to the corresponding naphthoquinone derivatives. 
The most potent compounds of the whole series, XVIa and XVIb, were tested for their  
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ability to downregulate the expression of Hsp90 client proteins in the squamous cell 
carcinoma A431 and the mesothelioma STO cells and showed nanomolar concentration 
cytotoxic activity.
36
  
 
 
 
 
 
Scheme 8. 1,3-Dipolar cycloaddition affords isoxazole-ring-fused isoquinoline-5,8-diones 
In 2014 a research group developed a one-pot, molecular iodine-induced, 1,3-dipolar 
cycloaddition/oxidative aromatization sequence to construct 2-substituted 
benzo[f]isoindole-1,3-dicarboxylates: a rapid and efficient strategy to construct 
biologically important compounds containing the quinone structure. Azomethine ylide 
XVII’ was formed in situ by reaction of N-methyliminodiacetate XVII with molecular 
iodine and showed that simple naphtoquinone reacted well generating the pyrroline-
derivate XVIII. After iodine-induced oxidative aromatization the tricyclic-fused system 
was obtained in good yield
37
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Scheme 9. One-pot, molecular iodine-induced, 1,3-dipolar cycloaddition/oxidative aromatization 
Even if 1,3-dipolar cycloaddition reactions between quinolinequinone and isoquinoline-
5,8-diones could provide a convenient and straighforward synthesis, leading to 
bioactive compounds, literature in this area is still vacant. Pyridine-fused indazol-4,7-
diones has been synthesized through aza-Diels Alder reaction (also called Ghosez-type 
reaction) between indazol-4,7-diones and acrolein N,N-dimethyl hydrazine
38
. Synthesis 
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of indazole derivates is by the way not trivial. Direct synthesis of simple quinone-fused 
pyrazoles had proved not to be achievable through 1,3-dipolar cycloaddition between 
nitrile-imines and p-benzoquinone
39
. Synthesis of the dienophiles had to involve 
oxidation to quinone moiety of the benzene ring of indazole itself. After nitration 
reaction that lead to 7-nitro indazole a 4 step synthesis afforded the desired indazol-4,7-
diones (Scheme 10). The high number of steps,  the use of toxic reagents and the 
difficulty encountered in the functionalisation of the dienophile, such as C-subtitution 
on the pyrazole moiety, made the reaction uneasy for further investigations.  
 
 
 
 
Scheme 10. Synthesis of tricyclic pyrazole-fused quinoline quinone 
Above all, this reaction approach is useless in synthesis of isoquinoline quinone 
derivate, because it concerns the use of N-vinyl imines that would required an inverse 
electron demand Diels Alder reaction, unfittable with the use of indazol-4,7-diones. 
Maybe for all these reasons a precise methodology and scope in the synthesis of 
tricyclic pyrazole-fused isoquinoline quinones is still yet unexplored. 
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2. Aim of the Thesis 
The importance of pyrazoles and isoquinoline-5,8-diones as potent biological scaffolds 
in medicinal chemistry has been widely underlined in the previous chapters. The aim of 
this thesis project is to synthetize a novel class of tricyclic polysubstitued pyrazole-
fused isoquinoline-5,8-diones and to investigate their biological potential against 
malignal tumor, acting as PI3K inhibitors. A highly convergent synthetic pathway to 
achieve these new polycyclic rings, involving  a 1,3-dipolar cycloaddition with 
isoquinoline-quinones as dipolarophiles will be investigated for the first time.  
Moreover, in order to ensure a suitable and scalable process, reaction conditions will be 
optimized for every step and the robustness of the method  will be tested in synthesizing 
differently substituted compounds, sharing the same central scaffold. Finally, with the 
help of Molecular Docking, the most suitable scaffolds will be chosen to check the 
potential inhibition of this newly synthetized compounds in preliminary in-vitro tests. 
Retrosynthetic analysis, starting from the final products, may help in recognizing the 
different intermediate scaffolds employed and foreseeing the synthetic strategy adopted. 
 
 
 
 
 
 
 
Following the most suitable retrosynthetic approach, due to the experience gained from 
our laboratory in [3+2] cycloaddition reactions, the central core will be formed through 
a telescopic two-step 1,3-dipolar cycloadditon followed by oxidation, between the ring-
fused quinone (dipolarophile, in red in retrosynthetic scheme) and the nitrilimine 
(dipole) derived from the hydrazonoyl chloride (in blue in retrosynthetic scheme). 
Optimization of reaction conditions, such as temperature, concentration, reaction 
initiators will be broadly studied in terms of yield and regioselectivity. Since none of the 
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two building blocks is commercially available, the synthesis of these two precursors 
will be widely investigated.  
Even if the synthesis of aryl-substituted hydrazonoyl chlorides, starting from the 
corresponding hydrazide, is already present in literature, an heteroaromatic variant, as 
far as we know, is still vacant; therefore a precise methodology will be defined.    
 
  
 
 
 
 
For the dipolarophile, literature presents many ways to obtain isoquinoline-quinones; 
however, sometimes the scope is restricted to a small range of amenable 
functionalization. Moreover, unsubstitued quinone moiety, needed in the subsequent 
1,3-dipolar cycloaddition step, is most often impossible to achieve. In addition, taylor 
made synthesis, designed to reach precise scaffolds, tunable in base of their bioactive 
capability, often require an inaccessible number of steps. This considered, our aim will 
be to find a step-economical and versatile synthetic pathway, in order to obtain 
polysubstitued isoquinoline-5,8-diones starting from commercially available and 
relatively cheap materials.  
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3. Results and Discussions 
3.1. Synthetic methology for the dipolarophile 
For the synthesis of isoquinoline-5,8-diones, a modification of a very well-known 
literature procedure seemed to be the most suitable starting point for our purpose. The 
reaction employed could be seen as a combination between the Hantzsch 
dihydropyridine synthesis, followed by oxydation, in which a cyclocondensation of in 
situ-generated enone and enamine species gives dihydropyridines (Scheme 11), and the 
Bolmann-Rahtz pyridine synthesis, in which the direct use of ynones, instead of enones, 
obviates the need for an aromatizing oxidation step to get the target pyridines (Scheme 
12). Although the Bohlmann-Rahtz Synthesis is more versatile, purification of the 
intermediate and the high temperatures required for the cyclodehydration are significant 
drawbacks that have limited its synthetic utility. 
 
 
 
 
 
 
Scheme 11.  Hantzsch Dyhydropyridine synthesis followed by oxidation in nitric acid 
 
 
 
 
Scheme 12. Bolhmann-Ratz pyridine synthesis that afford substitued pyridine without oxidation needed 
 
In 2006, Valderrama et al.
40
 synthetized a series of 1-Aryl-substitued 
aminoisoquinolinequinones, studying their antitumoral activity. Starting with a 
  
 
 
 
29 
 
preformed 3-aminocrotonate, as enone, bis-conjugated acetyl-1,4-benzoquinones, as 
Micheal acceptors,  and  MnO2 as the oxidant, they obtained substituted isoquinoline-
5,8-diones with acceptable yields (Scheme 13). 
 
 
 
 
 
Scheme 13.  Cyclocondensation reaction between enaminone and quinone 
 Interestingly, they observed that the reaction could be carried out in a one-pot 
procedure, starting directly from a suitable 2-carboxy hydroquinone, exploiting the fast 
redox equilibrium of this species with the oxidizing agent used for the final irreversible 
step. After some screening, they found that the use of 2 equivalents of Ag2O acting as 
an oxidant for both the initial formation of the Micheal acceptor and for the final step 
regeneration of the quinone moiety, gave the desired products in good yields (Scheme 
14)
41
.  
 
 
 
 
 
 
 
 
Scheme 14. One-pot Micheal addition-cyclocondensation-oxydation reaction  
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In this work, Valderrama’s group explored mainly the screening of possible 
substitutions in the 1-position of  the quinolinic ring (Scheme 14, column R
1
) and, 
partially, in the electron-withdrawing group, employing methyl 3-aminocrotonate to 
afford a carboxylated substitution, or  3-amino-penten-2-one for an acetyl-substituted 
isoquinolinequinone (Scheme 14 column R
2
).  
 
3.1.1 Synthesis of Isoquinoline-5,8-diones 
 
Considered the accessible starting material, the good yields and the mild conditions, we 
thought that the previously described pathway could be a simple and straightforward  
method to synthesize  the dipolarophiles of interest, but the lack of a consistent scope on 
the 3-position of the ring, with more bioactive and challenging moieties, rather than a 
simple methyl substituent, was undoubtedly a drawback for our purpose. For this 
reason, we decided, initially, to maintain the same EWG (Electron Withdrawing Group) 
employed by Valderrama (COOMe) and expand the outlook on the substitution of the  
3-position. As shown in Scheme 14, for the synthesis of the previously mentioned 
isoquinoline-5,8-diones a cyclocondensation reaction between 2,5-
dihydroxybenzaldheyde and enaminones has to be employed. While 2,5-
dihydoxybenzaldheyde is commercially avaible, enaminones were synthetized, 
following a literature procedure, from β-keto esters. These 1,3-dicarbonilic compounds 
were also synthetized according to a reported procedure.
42
 For the synthesis of  β-keto 
esters, well-established procedures are Claisen condensation and Blaise reaction, but 
major drawbacks such as use of toxic reagents and formation of side products are 
involved. So, we decided to use a methodology involving the formation of the enolate 
of a substitued methyl ketone (by reaction with NaH in boiling toluene), followed by its 
nucleophilic attack on dimethyl carbonate. β-Keto esters 2 were obtained with excellent 
yields and often with no need for further purification. Substrates employed are shown in 
Scheme 15. 
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Scheme 15. Synthesis of substituted enaminones  
The second step consisted in an amination reaction using ammonium acetate (NH4OAc) 
as the source of ammonia in a condensation-tautomerization process involving the 
ketonic carbonyl of keto esters 2. Enaminones 3a, 3b and 3c were easily obtained after 
purification by column chromatography on silica-gel. Subsequently, the reactivity of the 
phenyl, 2-furyl and 3-pyridyl derivates 3a, 3b and 3c was tested to see if aryl and 
heteroaryl substituents on the 3-aminoacrylate were well tolerated in the synthesis of the 
desired isoquinoline-5,8-quinones. The cyclocondensation reaction was carried out 
using the previously described method. As it is possible to see in the proposed 
mechanism showed in Scheme 16, according to the literature, the first step is the 
formation of the Micheal acceptor (quinone I) from the oxidation of the starting 
material performed by the first equivalent of Ag2O, followed by the attack of the 
enamine in the most reactive position. Tautomerism of the imine III to a more stable 
conjugated enamine IV triggers the 6-exo-trig cyclocondensation. Tautomerization of 
ketone V leads then to a more stable 5,8-dihydroxyisoquinoline, due to aromatization of 
the two condensed rings. As the last step, the second equivalent of Ag2O affords the 
oxidized form 5, as the reaction product. 
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Scheme 16. Proposed mechanism for the synthesis of isoquinoline-5,8-diones 
Scheme 17 shows the results for the isoquinoline-5,8-diones formation. Initially, 
monitoring the reaction by TLC, we found a plateuax in the conversion after 6 hours, in 
which both hydroxyquinone and enaminone were still observable. After the addition of 
further 0.5 equivalents of Ag2O the reagents were no longer detectable by TLC analysis. 
This behavior was imputable to an in situ degradation of silver oxide; thus, we decided 
to add the oxidizing agent portionwise, 0.4 equivalent hourly in 5 hours and then to stir 
overnight.  
 
 
 
 
 
 
 
Scheme 17. Reaction to afford different substituted isoquinoline-5,8-diones  
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The reaction afforded almost pure products 5, that could be purified by a short plug of 
silica gel in the case of phenyl 5a and 2-furyl 5c substituted isoquinoline-5,8-diones and 
by column chromatography on silica gel with the 3-pyridyl substituent 5b.   
After the good results obtained with the screening of different substitutions on the 3- 
position of the isoquinoline-5,8-dione substrates, we investigated the possibility of 
enhancing the scope of the Electron Withdrawing Group present at the 4-position, 
deriving from the enaminone. For its enhanced EWG potential, the possibility for 
further functionalizations substitution of methyl ester with a nitro group seemed the 
most attractive idea. Using procedures previously described in literature
43
 we decided to 
synthetize β-amino nitrolefins, laying our attention on the maintenance of the same 
substitution pattern of the previously synthesized products 5. Except for commercialy 
avaible β-nitrostyrene 7a, nitroolefins 7b and 7c had to be synthetized. Thus, starting 
from commercially available 2-furfural 6c and 3-pyridin carboxaldheyde 6b we 
obtained the correspondent nitroolefin 7b and 7c through Henry reaction, followed by 
heat-mediated dehydration. Sometimes, especially for pyridine derivative 7b, the 
intermediate aminoalchol was still observable in the crude mixture (by means of  
1
H 
NMR analysis) and an acidic work-up with TFAA (trifluoroacetic acid) was required, in 
order to favor water elimination.  
 
 
 
 
 
 
 
 
 
 
Scheme 18. Pathway through the synthesis of  β-amino nitrolefins  
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The second step of the process is an aza-nitro-Micheal addition of pre activated 
methoxylamine on the nitroolefin. The addition intermediated was filtered and added 
dropwise to a solution of potassium tert-butoxyde, to give elimination of the methoxide 
ion to form a stable conjugated β-amino nitroolefins 8. This synthesis was performed in 
multiple gram scale with non-consistent loss of yield. Despite the good yield of phenyl 
and furyl derivatives 8a and 8c, some difficulties were encountered in the purification 
of the substrate containing 3-pyridyl moiety 8b due to the extreme insolubility of the 
desired product. As anticipated before, we then tested the efficacy of the β-amino 
nitroolefins in the cyclocondensation reaction for the synthesis of the isoquinoline-5,8-
dione scaffolds. The reaction was carried out in the same conditions as before (Scheme 
17). We thought that, due to a less nucleophilic enaminone, both on the carbon that 
undergoes the Micheal addition and on the amine, coordinated through hydrogen 
bonding to the nitro group (NMR analysis shows two different aminic hydrogen, one in 
a very deshielded region), we would notice a dramatic decrease of reactivity. 
Interestingly, as it is possible to see in Scheme 19, even if a lower degree of reactivity 
was observed, we were able to achieve good yields in every case. Moreover, the 
decrease in the yield, compared to products 5, can be attributed to the fact that nitro-
isoquinoline-5,8-diones 9 needed always to be purified by column chromatography, in 
order to obtain a product of suitable purity (see Scheme 10 for comparison).  
 
 
 
 
 
 
 
 
 
Scheme 19. Screening of feseability of the reaction to afford different substituted 4-nitro-isoquinoline-
5,8-diones  
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3.2. Synthesis of the hydrazonoyl chloride, precursor of the 1,3-
dipole 
Afterwards, we moved to the synthesis of the precursor of the nitril-imine. A well-
established procedure, previously employed by our research group for the synthesis of 
C-aryl hydrazonoyl chlorides, was optimized for an hetero-aromatic ring substitution. 
As seen in the previous chapter, the disconnection approach leading to the precursor, 
started with the synthesis of the hydrazide by nucleophilic acyl substitution of a suitable 
hydrazine on a previously activated carboxylic acid.  
  
 
 
 
 
The 2-pyridyl and halogen-containing aryl moieties were chosen both to investigate for 
the first time an heteroaryl ring placed on a nitril-imine and for their remarkable 
biological properties, as already established in previous chapters (1.3). Initially, 
activation of the carboxylic group of picolinic acid 10 was accomplished via acyl-
chloride formation. The first attempt was a direct chlorination of picolinic acid (3-
pyridyl-carboxylic acid, 10) with thionyl chloride (SOCl2) to form intermediate 
picolinoyl chloride (hydrochloric salt) 11, followed by nucleophilic substitution of 2-
chloro-phenyl hydrazine 12, with 2 eq. of triethylamine (Scheme 20). The reaction 
afforded the desired hydrazide 13 in poor yield (34 %) due to difficulties encountered in 
handling the unstable and poorly soluble intermediate 11. 
 
 
 
 
Scheme 20. Hydrazide formation by activation through acyl chloride formation 
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Another activation exploiting the acyl chloride was then tested. The formation of 
picolinoyl chloride 15 was achieved by activation of sodium picolinate 14 with a large 
excess of (COCl)2 (oxalyl chloride ) and catalytic DMF (dimethylformamide). The 
formation of NaCl, instead of HCl in the chlorination process, avoids the formation of 
insoluble 11 in favor of the corresponding free, soluble form 15. Synthesis of hydrazide 
13 in the same abovementioned conditions afforded the desired product in improved 
67% yield after biphasic trituration in water- EtOAc/Hexane (4:3) and filtration (the 
high insolubility of 13 was exploited). 
 
 
 
 
 
Scheme 21. Formation of picolinoyl chloride with oxalyl chloride and nucleophilic substitution with 
hydrazine 
 
Due to the uneasy work-up for the removal of excess of oxalyl chloride, and to the need 
for improving the step-economy and the scalability of the substrate preparation 
(employing a high amount of (COCl)2 also poses safety problems), we explored a direct 
activation of picolinic acid 10. Pyridine-2-carboxylic acid 10 was reacted with DCC 
(dicyclohexylcarbodiimide) and NHS (N-hydroxysuccinimide), in anhydrous THF, to 
form in situ an activated NHS-ester 16 that can undergo direct substitution by pre-
activated hydrazine 12. After biphasic reslurry in water-EtOAc/Hexane (4:3), filtration 
and recrystallization from ethanol to remove the DCU (dicyclohexylurea) coproduct, 
desired product 13 was obtained in quantitative yield.  
As mentioned in the previous chapters, halogen-containing drugs are an important 
family of bioactive pharmaceutical compounds and the possibility to fine tune an 
halogen substitution in different ways is an important tool in synthetic organic 
chemistry. For this purpose, the shown process is to be considered a highly efficient 
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methodology, due to the large number of cheap, commercially available halogen-
substitued phenyhydrazines. For these reasons hydrazides 13a, 13b and 13c derived 
from differently halogen-substituted hydrazines 12a, 12b and 12c were prepared. The 
desired product was always achieved with good yields. The minor yield obtained for the 
the bis-fluorinated hydrazide 13c can be imputable to a different purification process: in 
fact, due to the higher solubility often showed by fluorinated molecules, the trituration-
recrystallization process was no longer exploitable and separation from DCU by column 
chromatography on silica gel was necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. Synthesis of halogen-substituted hydrazides through activation of carboxylic acid with 
DCC/NHS  
 
The last step of the synthesis was the formation of hydrazonoyl chlorides bearing an 
hetero-aromatic ring such as 2-pyridyl. Even if the procedure adopted was identical to 
the one reported for aryl-substituted hydrazide, the formation of heteroaryl-hydrazonoyl 
chlorides is yet unexplored. Reaction was performed in Appel-like conditions: CCl4 
(methane tetrachloride) and PPh3 (triphenylphosphine) were employed as chlorinating 
agents, in anhydrous acetonitrile (ACN). In the three cases we observed a very clean 
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reaction. TLC and 
1
H NMR on the crude product showed only the presence of 
hydrazonoyl chloride and triphenylphopshine oxide. After purification on short column 
chromatography we obtained the desired products 17 with comparable literature yields 
(Scheme 23).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 23. Synthesis of hydrazonoyl chloride starting from hydrazide in Appel-like condition 
 
3.3. 1,3-Dipolar cycloaddition of the nitril-imine with the 
isoquinoline-5,8-diones followed by oxidation: synthesis of 
tricyclic  ring-fused pyrazoles 
With the dipolarophiles (5 and 9) and the precursor of the 1,3-dipole 17 in hand, the 
feasibility, the regiochemistry and the best reaction conditions for the [3+2] dipolar 
cycloaddition-oxydation were then investigated. 1,3-Dipolar cycloaddition between 
isoquinoline-5,8-diones and nitrile-imines has never been explored and hides problems 
of controlling both reactivity and regioselectivity. Base-mediated in situ formation of 
nitrile-imine 17’ from hydrazonoyl chloride 17, affords the 1,3-dipole, that captures the 
dipolarophile (isoquinoline-5,8-dione derivates 5 or 9) to give non-aromatic pyrazolines 
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A and B. In the first step the rate of formation of the reactive species is fundamental and 
good reaction outcomes depend on the stability of the nitrile-imine, that could undergo 
unwanted dimerization or degradation processes, compared to the capability of the 
dipolarophile to perform the cycloaddition reaction. On the other hand, a regio-
selectivity problem is present. Isoquinoline-5,8-diones bear an unsymmetrical di-α,β-
unsatured ketone portion that has two resonance forms a and b that share the 
characteristics to react with nitrile-imine 17’ to afford regioisomeric ring-fused 
pyrazoline  derivates A and B respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. 1,3-Dipolar cycloaddition pathway between in situ generated nitrilimine and isoquinoline-
5,8-diones 
The previously cited Valderrama’s work shows that nucleophlic attack on substrates 
like 5 or 9, happens at the 7-position, clarifying the preferential location  of the LUMO 
site. Therefore the HOMO site of the nitrile-imine (N atom of the 1,3 dipole moiety) 
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should attack the C-7 position rendering regioisomer A as the major product. 
Nevertheless, cycloaddition reactions are often much more complicated and sometimes 
unpredictable. Moreover, if it is the EWG group on the adjacent ring that guides the 
regiochemistry, a remote and tunable control of regioselectivity can be achieved. 
At the end, the oxydation step, affording aromatization of pyrazolines A and B into 
pyrazoles 18 and 19 proved to be a rather trivial and well-established process, borrowed 
from previous works of the research group. The whole reaction pathway is summarized 
in Scheme 24. 
 
3.3.1 Optimization of reaction condition 
 
We therefore started to investigate the reaction conditions to perform the 1,3-dipolar 
cycloaddition reaction. Employing isoquinoline-5,8-diones 5a or 9a (dipolarophiles) 
and hydrazonoyl chloride 17a (precursor of the 1,3-dipole, nitrile-imine) as model 
substrates, we tested the effect of different bases, as initiators for the formation of the 
nitrile-imine, different temperatures, solvents and reaction times on the yield of the 
reaction and the regioisomeric ratio. The oxidation step that followed the cycloaddition 
reactions, involved always suspension of the cycloaddition crude product in a mixture 
of THF and water and treatment with cerium ammonium nitrate (CAN). This proved to 
be efficient enough and did not need any optimization. Results are summarized in Table 
2. 
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(a) Reaction conditions: Sealed tube 5a/9a (0.1 mmol), base (2.5 of 17a), solvent (0.5 μL); then 
CAN (2.5 eq), THF/H2O 8:6 (3.5 mL), 0 °C, 2 h. (b) Yield of 18a isolated after column 
chromatography, referred to 5a/9a. (c) 0.021 mmol 17a was added hourly in 6 h until the necessary 
amount. (d) in presence of 0.1 mmol of Schreiner’s thiourea.  
Table 2. Screening of 1,3-dipolar reaction conditions 
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Triethylamine, the most employed base for the formation of  nitrile-imines, was found 
to be too reactive, leading almost instantaneously to the formation of tar-like 
decomposition products. Solvents and reaction temperatures did not improve much the 
reaction outcomes in these cases (entries 4, 5 and 6). Nevertheless, the process seemed 
to be promisingly feasible and quite regioselective. With our pleasure, we found that 
silver carbonate, which is reported to react differently from TEA in the formation of the 
nitrilimine,
44
 improved greatly the conversion of the reagents into the desired products 
although with a low detriment in the regioisomeric ratio. With small case-by-case 
adaptations we were able to obtain clean and decomposition products-free crudes (by 
1
H-NMR) and greater yields after purifications (entries 9, 10 and 11). Interestingly, we 
found that when 1 equivalent of Schreiner’s thiourea was added in the reaction mixture, 
we had a better regioselectivity, maybe imputable to the coordination of the thiourea to 
the nitro-group that enhanced its electron-withdrawing ability and presumably 
confirming the previously reported hypothesis concerning the regiocontrol. 
 
3.3.2 Screening of the substitution on both the cycloadditition 
reaction partners: synthesis of a class of triclycic ring-fused 
pyrazoles 
 
Thereafter, a series of substituted pyrazole-fused isoquinoline-5,8-diones were 
synthetized, starting from differently halogen-substituted hydrazonoyl chlorides 17a, 
17b, 17c and aryl- or heteroaryl-substituetd isoquinoline-5,8-diones (5a, 5b, 5c and 9a, 
9b, 9c). 
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(a) Reaction conditions: Sealed tube 5a/9a (0.1 mmol), base (2.5 of 17a), dioxane (0.5 μL); then 
CAN (2.5 eq), THF/H2O 8:6 (3.5 mL), 0 °C, 2 h. (b) Yield of no. M isolated after column 
chromatography, referred to 5a/9a. (c) 0.021 mmol 17a was added hourly in 6 h until the necessary 
amount. 
Table 3. Synthesis of different substituted pyrazole-fused isoquinoline-5,8-diones 
Subjecting to the optimized reaction conditions the previously mentioned substrates, we 
found that aryl and heteroaryl substituents on the isoquinoline-5,8-dione scaffold were 
well tolerated and afforded  good yields and almost pure crude products in both the 
regioisomeric forms. Decreased yield observed with the 2-pyridyl moiety were not 
attributed to a different reactivity, but to a more insoluble reagent that did not undergo 
full conversion with the applied reaction conditions.  
These good results considered, this method represents, to our knowledge, the only 
straightforward synthetic strategy to afford triclyclic ring-fused pyrazoles. Moreover, it 
also proved to be better performing, in terms of overall yield, compared to other very 
similar synthetic sequences.
45
  
 In order to attribute the exact structure of the major regioisomer, X-Ray diffraction 
analysis was performed on a single crystal of product 26. The structure shown is in 
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complete agreement with the theoretical and experimental studies conducted by our 
research group and reported in the introduction and with the previously formulated 
hypothesis (vide supra). 
 
 
 
 
 
 
 
Fig. 23 X-ray structure of the major regioisomer (Blue= Nitrogen, Red= Oxygen, Grey=Carbon, White= 
Hydrogen, Yellow=Fluorine) 
 
3.4. Molecular Docking and in vitro cytotoxic evaluation: pyrazole-
fused isoquinoline-5,8-diones as a class of  promising 
antitumoral agent  
 
As already been said in previous chapters, Phosphatidylinositol-4,5-bisphosphate 3-
kinase (also called phosphatidylinositide 3-kinases, phosphatidylinositol-3-kinases, PI 
3-kinases, PI(3)Ks, PI-3Ks or by the HUGO (Human Genome Organization) official 
stem symbol for the gene family, PI3K(s)) are a family of volved in cellular functions 
such as cell growth, proliferation, differentiation, motility, survival and intracellular 
trafficking, which in turn are involved in cancer. Since there are a number of different 
classes and isoforms of PI3Ks, Structure-Activity Relationship (SAR) studies were 
carried from collaborators of our research group to test the potential anticancer activity 
against PI3Kγ isoform of the same protein, that is thought to be an important modulator 
of extracellular signals, including those elicited by E-cadherin-mediated cell-cell 
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adhesion, which plays an important role in maintenance of the structural and functional 
integrity of epithelia. In addition to its role in promoting assembly of adherens 
junctions, the protein is thought to play a pivotal role in the regulation of cytotoxicity in 
cancer cells. We wanted to investigate either some already synthesized molecules or 
other ones bearing possible functionalization that could be made thinking about the 
reactivity of our building blocks, in order to prove, not just the efficacy of a singular 
candidate, but of a whole class of biologically active, easily obtainable and fine tunable 
molecules. Fig. 24 shows protein PI3Kγ taken from RCBS Protein Data Bank. The 
active site is clearly visible on figures underling also the “small entrance” of the site, 
that justifies our 
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Fig. 24 Computational modelling of ligand-PI3K’s active interaction 
 
choice of the ligand with flat aryl and heteroaryl moieties that allows a favorable 
conformation to slip into the pocket. However, it seems remarkable the ability of all the 
docked ligands to fit in such an uneasy opening space. To test the Binding Energy and 
calculate the theoretical IC50, all the molecules docked were first optimized 
geometrically at physiological pH and Temperature through mechanical calculation in 
Gaussian, then the output was launched in AutodockTools, in a pre-optimized protein, 
that gave the results showed in Table 4.  
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Table 4. Docking screening on target molecules containing tricyclic pyrazole-fused isoquinoline-5,8-
diones core 
All the molecules tested were thought on the basis of the reactivity of our precursors by 
adding typical moieties found in several bioactive compounds such as amide group, aryl 
or heteroaryl substituents. Substitution on the N-aryl ring, for example, with aniline or 
2-aminopyridine could be synthetized by a metal-mediated amination reaction, like 
direct Buchwald-Hartwig coupling on bromine derivative 24, or Cham-Lam coupling
46
 
on a pre-formed boronic acid. Amide formation could be carried out with a series of 
steps, involving saponification, activation of the acid and amination, for compounds 21, 
22 and 23, deriving from –COOMe substituted cycloadducts, or by reduction of nitro-
group and amidation with anhydrides of acyl chlorides for nitro-derivates 18, 19, 20, 24, 
25 and 26.  
This theoretical investigation with different functionalizations showed pyrazole-fused 
isoquinoline-5,8-diones as a promising class of phosphoinositide 3-kinase inhibitor 
(PI3K inhibitor) by inhibiting one or more of the phosphoinositide 3-kinase enzymes, 
which are part of the PI3K/AKT/mTOR pathway, an important signaling pathway for 
many cellular functions such as growth control, metabolism and translation initiation 
which may result in tumor suppression. Interestingly, our pre-functionalized scaffolds, 
bearing a chlorine atom in the ortho position and two fluorine atoms in the ortho and 
para positions resulted in good binding energy values, demonstrating the capability of 
the central tricyclic scaffold alone in stabilizing the ligand-protein system. Moreover, 
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these substrates were found to be peculiar for two main reasons. One, in the 
conformational optimization analysis with Gaussian interface, they showed only one 
energetic cluster of population at the minimum binding energy, meaning that just one 
conformation was found inside the protein. Second, a new π-cation interaction was 
found between one hydrogen of a protonated primary amine of LYS890 and the 
delocalized π system of halogen-substituted aryl group. These two characteristics were 
enhanced with the ortho-para fluoride substitution. For these reasons, we decided to 
functionalize compounds 18 and 25 to effectuate preliminary in vitro studies on the 
potential citotoxycity of these candidates. We then envisaged to reduce the nitro-group 
of our products in order to get a compound that would be more suitable for in vitro tests 
(more water-soluble, for instance) and to show the potential of the scaffold itself by 
keeping a relative low number of elaboration steps. Reduction of the nitro group of 18 
into arylamine 27 was achieved by catalytic hydrogenation using HCOONH4 
(ammonium formate) as hydrogen source, 10% Pd on activated carbon as catalyst and 
degassed MeOH as solvent. Product 9 was thus purified by column chromatography and 
obtained in 52% yield. (Scheme 25) 
 
 
 
 
 
 
Scheme 25. Reduction of 18 with ammonium formate as a source of hydrogen to afford 1-amine moiety 
 
We then thought that reducing the nitro group of the isoquinoline-5,8-dione before the 
cycloaddition, might have enhanced the reaction yield due to a more simple substrate. 
That was confirmed by conducting the reaction in the same conditions. TLC analysis 
showed a complete conversion after 1 hour and afforded 3-phenyl-4-amino 
isoquinoline-5,8-dione 28 in 92 % yield with no need for further purifications. 
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Scheme 26. Reduction done directly on the nitro-isoquinoline-5,8-dione 
 
We then tried the 1,3-dipolar cycloaddition reaction on compound 28 in the same 
conditions as shown in Scheme 26 and, interestingly, we envisioned an inversion of 
regioselectivity that lead to the preferential formation of 29b in 4:1 ratio. 
 
 
 
 
 
Scheme 27. Cycloaddition reaction between pre-reduced amino-isoquinolinequinone 
 
Finally, in the last part of this work, we choose two (27 and 30) candidates that have 
been sent to the Biology Laboratory under the supervision of Doctor Mario Chiariello, 
Istituto Toscano Tumori, Siena. This collaborating group performed a first test of cell 
viability in vitro on T98G cell line of a solid brain tumor, the Glioblastoma Multiforme.  
As it can be seen in Fig. 24, high cell mortality with very interesting IC50’s have been 
obtained with both molecules. Indeed, the range 7-50 micromolar represent promising 
values which are comparable with already marketed drugs as reported in the literature
47
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These compounds represent preliminary and interesting examples of the final molecules 
we wish to test once the amidation reactions together with a complete set of docking 
studies will be available.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 IC50 values calculated through in vitro test on T98G cell. Red curve (1) corresponds to compound 
27, green curve corresponds to compound 30.  
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4. Conclusions 
In conclusion, a class of tricyclic polysubstitued pyrazole-fused isoquinoline-5,8-diones 
has been synthetized for the first time.  
The robustness of the one-pot oxidation-Micheal addition-cyclocondensation reaction 
has been tested chequering different potentially biological active aryl- and heteroaryl- 
substituents in 3-position, filling up the lack of investigation in these interesting 
medicinal chemistry building blocks.  
We synthetized, to our knowledge, the first example of N-heteroaryl nitrile-imine and, 
starting from different halogen-substituted hydrazines, we synthetized a series of 
hydrazonoyl chlorides optimizing the reaction conditions in order to get a scalable, 
good-yielded and step-economical two-passage synthesis for the nitrile-imine precursor 
from relatively cheap and commercially available starting materials.  
The synthesis of yet unexplored tricyclic-fused pyridine-quinone-pyrazole core has 
been our main issue. A straightforward procedure, namely 1,3-dipolar cycloaddition 
followed by oxidative aromatization, established by our research group, has been 
employed. Screening of reaction conditions and characterization studies about the 
regioselectivity have been successfully performed and a class of complexes and 
polysubstituted scaffolds were synthetized with 36 % global yield in the major product 
(calculated for compound 18), which is comparable or, in some cases, much higher than 
currently commercially available pyrazole-containing drugs.  
Interestingly, a way to afford both the two regioisomers, by reducing before or after the 
cycloaddition reaction, the –NO2 moiety on the isoquinoline-5,8-dione ring, has been 
developed.  
Through Molecular Docking calculations we envisioned that our scaffolds stand as a 
whole new class of promising candidates as PI3K inhibitors for anticancer therapy. 
Finally, high purity samples of target compounds 27 and 30 have been obtained. They 
showed a good result of IC50 towards one type of brain cancer cells in a first test in vitro 
performed by a collaborating group. 
A first aim of future studies, the inversion of regioselectivity observed considered, will 
be to test the cytotoxic activity of both regioisomers of the same molecule on different 
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cell lines. A second objective is to test whether our molecules bring a real interaction 
with PI3K, from the biochemical point of view. 
However, with the results obtained, we have shown that the planned backbone is well 
suited to act as a cytotoxic agent on cancer cell lines, and for this reason further studies 
are ongoing in our research group.  
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5.  Experimental section 
 
General Methods. 
1
H, 
13
C NMR spectra were recorded on a Varian AS 300, 400 or 600 
spectrometer. Chemical shifts (δ) are reported in ppm relative to residual solvent signals 
for 
1
H and 
13
C NMR. Multiplicity is explained in brackets as follow: “s”, singlet; “d”, 
doublet; “t”, triplet; “q”, quadruplet; “sept”, septuplet; “m”, multiplet; a “b” before the 
letter means “broad”.  
 
Materials. Analytical grade solvents and commercially available reagents were used as 
received. Anhydrous THF was obtained by standing overnight on KOH, filtration 
through a short pad of basic alumina and distilled over Na/benzophenone. All the 
reactions demanding anhydrous conditions were performed in nitrogen atmosphere, 
passed through CaCl2 and silica gel with indicator. Anhydrous toluene was obtained by 
distillation on Na. Dry DMF and ACN was obtained by overnight standing on activated 
4 Å molecular sieves. Degassed MeOH was obtained by bubbling a nitrogen flux in an 
ice bath. 
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5.1. Synthesis of the dipolarophile 
5.1.1 General method for the  synthesis of β-ketoesters  
 
To a dried 100 ml RBF (round bottom flask) were added NaH (2.2 g, 60% w/w, 56 
mmol), dimethyl carbonate (3.6 g, 40 mmol) and toluene (20 mL) under nitrogen. After 
the mixture was heated to reflux, a solution of 3 (20 mmol) in toluene (10 mL) was 
added dropwise in 30 minutes. After the evolution of hydrogen ceased, the reaction was 
cooled down to room temperature. The reaction system was then diluted with 200 mL of 
EtOAc. The organic layer was separated, washed with brine (20 mL) and dried over 
MgSO4. The crude product was evaporated in vacuo and the residue was purified by 
column chromatography on silica gel with EtOAc/Hexane (1:3) to give the desired 
product.
 1
H NMR analysis were comparable to the one already present in literature
42
. 
 
5.1.2 General method for the  synthesis of enaminones 
 
A solution of  β-ketoesters (12 mmol) and NH4OAc (1.9 g, 24 mmol) in methanol (12 
mL), under nitogen atmosphere, was stirred under reflex overnight. The solvent was 
removed under reduced pressure and the residue was suspended in EtOAc (30 mL). The 
insoluble solid was filtered off and washed with EtOAc. The combined filtrate was 
washed with water and brine and dried over MgSO4. The crude product was evaporated 
in vacuo and the residue was purified by column chromatography on silica gel with 
EtOAc/Hexane (1:1). 
Experimental data: 
 
Methyl (Z)-3-amino-3-phenylacrylate (3a); 
1
H NMR (300 MHz, CDCl3) δ 7.55-
7.51 (m, 2H), 7.47-7.36 (m, 3H), 4.97 (t, J = 0.7, 1H), 3.70 (s, 1H) ppm. 
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Methyl (Z)-3-amino-3-(pyridin-3-yl)acrylate (3b); 
1
H NMR (300 MHz, 
CDCl3) δ 8.80 (dd, J1=2.4, J2=0.7, 1H), 8.68 (dd, J1=4.8, J2=1.6, 1H), 7.83 (dt, 
J1=8.0, J2=1.9, 1H), 7.36 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H), 4.97 (s, 1H), 3.73 
(s, 1H)   ppm. 
 
Methyl (Z)-3-amino-3-(furan-2-yl)acrylate (3c); 
1
H NMR (300 MHz, CDCl3) δ 
7.48 (dd, J1=1.8, J2=0.8, 1H), 6.75 (dd, J1=3.5, J2=0.7, 1H), 6.42 (dd, J1=3.5, 
J2=1.8, 1H), 5.14 (s, 1H), 3.70 (s, 3H)   ppm. 
 
 
5.1.3 General method for the  synthesis of β-nitroolefins 
 
Freshly distilled aldehyde (50 mmol) was added to a stirred solution of ammonium 
acetate (0.96 g, 0.25 eq.) in dry nitromethane (50 mL) at 90
o
C. The mixture was heated 
at reflux overnight, cooled to room temperature, poured into water and extracted with 
diethyl ether (3 × 50 mL). The extract was washed with brine, dried over MgSO4, 
filtered and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (EtOAc/Hex 1:2) to give the desired product. 
1
H NMR 
analysis were comparable to the one already present in literature
43
. 
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5.1.4 General method for the  synthesis of β-amino nitroolefins 
 
To a solution of methoxylamine-HCl (4.26 g, 1.1 eq.) in dimethylformamide (75 mL) 
was added Triethylamine (6.85 mL, 1.1 eq.) at 0
o
C in an ice bath. Nitroolefin (43.5 mol) 
was added and stirred at 0
o
C for 15 min then at rt for 5 min. The precipitate was 
removed by filtration and wash the solid with a small amount of DMF. The combined 
filtrate were placed  into an addition funnel and add dropwise over 30 min to potassium 
t-butoxide (10.15 g,  2 eq.) in DMF (100 mL) at 0
o
C. The bath was removed  and the 
mixture was stirred at rt for 30 min. After the quenching of the reaction with sat. NH4Cl 
(30 mL). the  volume was reduced in half in vacuo and then extracted with CH2Cl2. 
Wash with water, brine, and dried over anhydrous MgSO4, filter and concentrate in 
vacuo to give the desired amino-nitroolefin..  
Experimental data: 
(Z)-2-nitro-1-phenylethen-1-amine (8a) 
1
H NMR (300 MHz, CDCl3) δ 9.07 
(bs, 1H), 8.81 (dd, J1=2.4, J2=0.7, 1H), 8.79 (dd, J1=4.8, J2=1.6, 1H), 7.78 (dt, 
J1=8.0, J2=1.9, 1H), 7.42 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H), 6.82 (s, 1H) ppm. 
(Z)-2-nitro-1-(pyridin-3-yl)ethen-1-amine (8b) 
1
H NMR (300 MHz, CDCl3) δ 
9.07 (bs, 1H), 8.81 (dd, J1=2.4, J2=0.7, 1H), 8.79 (dd, J1=4.8, J2=1.6, 1H), 7.78 
(dt, J1=8.0, J2=1.9, 1H), 7.42 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H), 6.82 (s, 1H), 
5.81 (bs, 1H)   ppm. 
3-(Furan-2-yl)-4-nitroisoquinoline-5,8-dione (8c) 
1
H NMR (300 MHz, CDCl3) 
δ   9.44 (s, 1H) 7.67 (dd, J1=1.8, J2=0.8, 1H), 7.41 (dd, J1=3.5, J2=0.7, 1H), 
7.06 (s, 2H), 6.83 (dd, J1=3.5, J2=1.8, 1H) ppm 
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5.1.5 General procedure for the synthesis of isoquinoline-5,8-
diones 
 
A suspension of 2,5-dihydroxybenzaldehyde (1.6 g, 10.1 mmol), enamine  (10 mmol), 
Ag2O (4.63 g, 20.2 mmol, stepwise hourly for 5 hours) and MgSO4 (5.5 g) in CH2Cl2 
(150 mL) was stirred at room temperature overnight. The mixture was filtered, the 
solids were washed with CH2Cl2 and the solvent removed under reduced pressure. 
When necessary, the residue was purify by column chromatography over silica gel 
(90:10 CH2Cl2/AcOEt) to yield pure isoquinolinequinone. 
 
Experimental data: 
 
Methyl 5,8-dioxo-3-phenyl-5,8-dihydroisoquinoline-4-carboxylate (5a); 
1
H 
NMR (300 MHz, CDCl3) δ 9.47 (s, 1H), 7.71-7.68 (m, 2H), 7.50-7.47 (m, 3H), 
7.0 (s, 2H), 3.48 (s, 3H)   ppm. 
 
Methyl 5,8-dioxo-3-(pyridin-3-yl)-5,8-dihydroisoquinoline-4-carboxylate (5b); 
1
H NMR (300 MHz, CDCl3) δ 9.67 (s, 1H), 8.94 (dd, J1=2.4, J2=0.7, 1H), 8.74 
(dd, J1=4.8, J2=1.6, 1H), 8.04 (dt, J1=8.0, J2=1.9, 1H), 7.43 (ddd, J1=7.9, J2=4.9, 
J3= 0.7, 1H), 7.10 (s, 2H), 3.93 (s, 3H)   ppm. 
 
Methyl 3-(furan-2-yl)-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylate (5c); 
1
H NMR (300 MHz, CDCl3) δ 9.35 (s, 1H) 7.63 (dd, J1=1.8, J2=0.8, 1H), 7.37 
(dd, J1=3.5, J2=0.7, 1H), 7.03 (s, 2H), 6.61 (dd, J1=3.5, J2=1.8, 1H), 4.10 (s, 
3H)   ppm. 
 
4-Nitro-3-phenylisoquinoline-5,8-dione (9a) 1H NMR (300 MHz, CDCl3) δ 
9.56 (s, 1H), 7.71-7.65 (m, 2H), 7.56-7.50 (m, 3H), 7.12 (s, 2H) ppm. 
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4-Nitro-3-(pyridin-2-yl)isoquinoline-5,8-dione (9b) 
1
H NMR (300 MHz, CDCl3) δ 
9.81 (s, 1H), 8.98 (dd, J1=2.4, J2=0.7, 1H), 8.80 (dd, J1=4.8, J2=1.6, 1H), 8.05 (dt, 
J1=8.0, J2=1.9, 1H), 7.46 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H), 7.13 (s, 2H) ppm. 
 
3-(Furan-2-yl)-4-nitroisoquinoline-5,8-dione (9c) 
1
H NMR (300 MHz, CDCl3) δ 
9.44 (s, 1H) 7.67 (dd, J1=1.8, J2=0.8, 1H), 7.41 (dd, J1=3.5, J2=0.7, 1H), 7.06 (s, 
2H), 6.83 (dd, J1=3.5, J2=1.8, 1H) ppm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
62 
 
5.2. Synthesis of the 1,3-dipole 
5.2.1 General synthesis of hydrazide 
 
To a solution of picolinic acid (30 mmol) and N-hydroxysuccinimide (30 mmol) in 
anydrous THF, N-dicyclohexylcarbodiimide (33 mmol) was slowly added under a 
nitrogen atmosphere at 0°C. The ice bath was then removed and the reaction mixture 
was stirred for 1h at rt. After that the reaction mixture was cooled again to 0°C and a 
previously formed suspension of  2,4-difluorophenylhydrazine hydrochloride (33 mmol, 
1.1 eq.) and triethylamine (1.1 eq) in anhydrous THF was added portionwise. The ice 
bath was removed and the reaction was stirred overnight at rt. The reaction mixture was 
dried in vacuo and then washed with H2O and EtOAc/EtPet 4:3 for 30 min. For 
compound 17a and 17b the reaction mixture was filtrated and the filtrate was 
recrystallized in EtOH (ca. 33 mL). 17c was, instead, directly washed with EtOAc and 
brine and purified by column chromatography on silica gel (EtOAc/Hex 1:2) to afford 
pure hydrazide. 
Experimental data: 
 
N'-(2-chlorophenyl)picolinohydrazide (16a)
  1
H NMR (300 MHz, CDCl3) δ 
10.78 (bs, 1H) 8.78 (dd, J1=2.4, J2=0.7, 1H), 8.05 (m, 2 H), 7.68 (dt, J1=8.0, 
J2=1.9, 1H), 7.62 (s, 1H),  7.36 (d, J=4.9, 1H), 7.18 (t, J=7.9, 1H), 6.8 (m, 2H) 
ppm. 
 
N'-(2-bromophenyl)picolinohydrazide (16b)
  1
H NMR (300 MHz, CDCl3) δ 
10.78 (bs, 1H), ), 8.71 (dd, J1=2.4, J2=0.7, 1H), 8.02 (m, 2 H), 7.63 (dt, J1=8.0, 
J2=1.9, 1H), 7.42 (d, J=4.9, 1H), 7.38 (s, 1H),  7.18 (t, J=7.9, 1H), 6.80-6.62 
(m, 2H) ppm. 
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N'-(2,4-difluorophenyl)picolinohydrazide (16c) 
1
H NMR (300 MHz, CDCl3) δ 
9.57 (d, J=3.6, 1H), 8.61 (ddd, J1= 5.0, J2=2.7, J3= 1.0, 1H), 8.17 (dt, J1= 7.6 , 
J2=1.1), 7.88 (dt, J1= 7.6, J2= 1.6, 1H), 7.51-7.48 (m, 1H), 7.0-6.7 (m, 3H), 6.34 
(d, J= 3.6, 1H). 
 
 
5.2.2 General synthesis of hydrazonoyl chloride 
 
In a round bottom flask, under nitrogen atmosphere, hydrazide (16 mmol), 
triphenylphospine (5.25 g, 20 mmol), tetrachloro methane (2 mL, 20 mmol) and 
acetonitrile (30 mL, passed overnight on 3 angstrom molecular sieves) were stirred 
overnight at room temperature.  The solvent was removed under reduced pressure and 
the crude product was purified by column chromatography on silica gel (Hexane/EtOAc 
5:1) to afford the desired hydrazonoyl chloride. 
Experimental data: 
 
(Z)-N-(2-chlorophenyl)picolinohydrazonoyl chloride  (17a)  
1
H NMR (300 
MHz, CDCl3) δ 8.84 (bs, 1H) 8.72 (dd, J1=2.4, J2=0.7, 1H), 8.19 (d, J=8.0 1H), 
7.97 (dt, J1=8.0, J2=1.9, 1H), 7.72 (d, J=4.9 1H),  7.53 (m, 2H), 7.18 (t, J=7.9, 
1H), 7.05 (t, J=7.9, 1H) ppm. 
 
(Z)-N-(2-bromophenyl)picolinohydrazonoyl chloride (17b) 
1
H NMR (300 
MHz, CDCl3) δ 8.81 (bs, 1H) 8.67 (dd, J1=2.4, J2=0.7, 1H), 8.09 (d, J=8.0 1H), 
7.89 (dt, J1=8.0, J2=1.9, 1H), 7.62 (d, J=4.9 1H),  7.23 (m, 2H), 7.12 (t, J=7.9, 
1H), 7.05 (t, J=7.9, 1H) ppm. 
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(Z)-N-(2,4-difluorophenyl)picolinohydrazonoyl chloride (17c)  1H NMR (300 
MHz, CDCl3) δ 8.89 (d, J=3.6, 1H), 8. 70 (ddd, J1= 5.0, J2=2.7, J3= 1.0, 1H), 8.09 
(dt, J1= 7.6 , J2=1.1), 7.61 (dt, J1= 7.6, J2= 1.6, 1H), 7.51-7.48 (m, 1H), 7.0-6.7 
(m, 3H), 6.34 (d, J= 3.6, 1H). 
 
5.3. General method for 1,3-dipolar Cycloaddition reaction 
To a stirred suspension of isoquinoline-5,8-dione (1 mmol) and Ag2CO3 (1.3 mmol) in 
anhydrous dioxane (4 mL), under nitrogen atmosphere at 50°C, was added hourly 
hydrozonoyl chloride (0.2 eq x 6) as solid until after 6 h whole 1.2 eq. were reached. 
The reaction mixture was stirred overnight. After the reaction was complete the mixture 
was cooled to room temperature, filtered through a plug of celite and evaporate in 
vacuo. The crude product was directly suspended in 100 mL 4:3 THF/water and cooled 
to 0°C. Cerium ammonium nitrate (CAN, 2.5 mmol) was added portionwise  and the 
reaction was stirred for 2 h. After the removal of THF in vacuo, the mixture was was 
extracted with EtOAc (3x75 mL) and brine (75 mL), dried over MgSO4 and evaporated 
in vacuo. The crude product was purified by column chromatography (EtOAc/EtPet 
2:1) to afford cycloaddition product. 
Experimental data: 
Methyl 1-(2-chlorophenyl)-4,9-dioxo-6-phenyl-3-(pyridin-2-yl)-4,9-
dihydro-1H-pyrazolo[4,3-g]isoquinoline-5-carboxylate (18) 
1
H NMR 
(300 MHz, CDCl3) δ 9.58 (s, 1H), 8.81 (dd, J1=2.4, J2=0.7, 1H), 8.33 
(dd, J1=4.8, J2=1.6, 1H), 7.90 (dt, J1=8.0, J2=1.9, 1H), 7.59 (m, 10H), 
7.43 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H),   4.03 (s, 3H)   ppm. 
 
Methyl 1-(2-chlorophenyl)-4,9-dioxo-3-(pyridin-2-yl)-6-(pyridin-3-yl)-
4,9-dihydro-1H-pyrazolo[4,3-g]isoquinoline-5-carboxylate (19) 
1
H 
NMR (300 MHz, CDCl3) δ 9.53 (s, 1H), 8.96 (d, J=1.8, 1H), 8.82 (dd, 
J1=4.8, J2=1.6, 1H),  8.75 (dd, J1=4.8, J2=1.6, 1H), 8.37 (dt, J1=8.0, 
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J2=1.9, 1H), 8.07 (dt, J1=8.0, J2=1.9, 1H), 7.91 (dt, J1=8.0, J2=1.9, 1H), 7.45 (m, 10H),  3.92 (s, 3H)   ppm. 
 
Methyl 1-(2-chlorophenyl)-6-(furan-2-yl)-4,9-dioxo-3-(pyridin-2-yl)-
4,9-dihydro-1H-pyrazolo[4,3-g]isoquinoline-5-carboxylate (20) 
1
H 
NMR (300 MHz, CDCl3) δ 9.39 (s, 1H), 8.82 (dd, J1=4.8, J2=1.6, 
1H),  8.40  (dt, J1=8.0, J2=1.9, 1H), 7.92 (dt, J1=8.0, J2=1.9, 1H), 
7.68-7.34 (m, 7H), 6.62 (dd, J1=3.5, J2=1.8, 1H)   4.14  (s, 3H)   
ppm. 
 
1-(2-Chlorophenyl)-5-nitro-6-phenyl-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (21) 
1
H NMR (300 MHz, 
CDCl3) δ 9.59 (s, 1H), 8.81 (dd, J1=2.4, J2=0.7, 1H), 8.35 (dd, 
J1=4.8, J2=1.6, 1H), 7.91 (dt, J1=8.0, J2=1.9, 1H), 7.75-7.50 (m, 9H), 
7.43 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H)   ppm. 
 
 
1-(2-Chlorophenyl)-5-nitro-3,6-di(pyridin-2-yl)-1H-pyrazolo[4,3-
g]isoquinoline-4,9-dione (22) 
1
H NMR (300 MHz, CDCl3) δ 9.52 
(s, 1H), 8.96 (d, J=1.8, 1H), 8.81 (dd, J1=4.8, J2=1.6, 1H),  8.73 (dd, 
J1=4.8, J2=1.6, 1H), 8.33 (dt, J1=8.0, J2=1.9, 1H), 8.07 (dt, J1=8.0, 
J2=1.9, 1H), 7.94 (dt, J1=8.0, J2=1.9, 1H), 7.45 (m, 10H)   ppm. 
 
 
1-(2-chlorophenyl)-6-(furan-2-yl)-5-nitro-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (23) 1H NMR (300 MHz, 
CDCl3) δ 9.44 (s, 1H), 8.81 (dd, J1=4.8, J2=1.6, 1H),  8.33  (dt, 
J1=8.0, J2=1.9, 1H), 7.90 (dt, J1=8.0, J2=1.9, 1H), 7.68-7.34 (m, 7H), 
6.62 (dd, J1=3.5, J2=1.8, 1H)   ppm. 
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1-(2-Bromophenyl)-6-(furan-2-yl)-5-nitro-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (24) 
1
H NMR (300 MHz, 
CDCl3) δ 9.45 (s, 1H), 8.81 (dd, J1=4.8, J2=1.6, 1H),  8.33  (dt, J1=8.0, 
J2=1.9, 1H), 7.91 (dt, J1=8.0, J2=1.9, 1H), 7.64-7.31 (m, 7H), 6.62 (dd, 
J1=3.5, J2=1.8, 1H)   ppm. 
 
5-amino-1-(2,4-difluorophenyl)-6-phenyl-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (30) 1H NMR (300 MHz, 
CDCl3) δ 8.73 (s, 1H), 8.71 (d, J= 1.9, 1H) 8.5 (d, J=4.8, 1H),  8.33  (dt, 
J1=8.0, J2=1.9, 1H), 7.90 (dt, J1=8.0, J2=1.9, 1H), 7.68-7.34 (m, 6H), 
6.62 (dd, J1=3.5, J2=1.8, 1H)   ppm. 
 
 
1-(2,4-difluorophenyl)-5-nitro-6-phenyl-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (26) 
1
H NMR (300 MHz, 
CDCl3) δ 9.60 (s, 1H), 8.81 (ddd, J1= 5.1, J2= 2.6, J3= 1.2 1H)  8.33  (dt, 
J1=8.0, J2=1.9, 1H), 7.91 (dt, J1=8.0, J2=1.9, 1H), 7.68-7.34 (m, 9H), 
ppm. 
 
 
1-(2,4-difluorophenyl)-6-(furan-2-yl)-5-nitro-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (25) 
1
H NMR (300 MHz, 
CDCl3) δ 9.46 (s, 1H), 8.81 (ddd, J1= 4.8, J2= 2.6, J3= 1.2 1H)  8.32  (dt, 
J1=8.0, J2=1.9, 1H), 7.88 (dt, J1=8.0, J2=1.9, 1H), 7.61-7.30 (m, 7H), 
6.62 (dd, J1=3.5, J2=1.8, 1H)   ppm. 
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5.4. General method for reduction 
In a round bottom flask equipped with a magnetic stirring bar and under nitrogen 
atmosphere, product  (6.0 mmol) and ammonium formate (3.43 g, 54.5 mmol) were 
dissolved in 60 mL of degassed MeOH and the solution was heated to 50 °C. 10% w/w 
Palladium on activated charcoal (0.23 g) was added and the reaction mixture was stirred 
at 90 °C for 5 h. 
Hereafter, the reaction mixture was filtered through a short plug of celite, washed with 
DCM (40mL) and evaporated in vacuo. The crude product was suspended in DCM (50 
mL), filtered again on celite and washed with DCM (50 mL) to give the amino-
substituted product. 
Experimental data: 
4-Amino-3-phenylisoquinoline-5,8-dione (28) 
1
H NMR (300 MHz, 
CDCl3) δ 8.69 (s, 1H), 7.70-7.66 (m, 2H), 7.59-7.50 (m, 3H), 6.98 
(d, J= 9.9, 1H), 6.93 (d, J=9.9, 1H)  ppm. 
 
  
5-amino-1-(2-chlorophenyl)-6-phenyl-3-(pyridin-2-yl)-1H-
pyrazolo[4,3-g]isoquinoline-4,9-dione (27) 
1
H NMR (300 MHz, 
CDCl3) δ 8.70 (s, 1H), 8.80 (dd, J1=2.4, J2=0.7, 1H), 8.35 (dd, 
J1=4.8, J2=1.6, 1H), 7.98 (dt, J1=8.0, J2=1.9, 1H), 7.75-7.50 (m, 9H), 
7.43 (ddd, J1=7.9, J2=4.9, J3= 0.7, 1H)   ppm. 
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